{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:03:39Z","timestamp":1789776219578,"version":"4.0.1"},"reference-count":137,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>Aging has long been implicated in the onset and progression of major retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Glaucoma is likewise increasingly recognized as an age-related disorder. Across these conditions, converging patterns of neurodegeneration and microvascular injury contribute to age-associated ocular decline. Structural and neuronal degeneration of the retina, including loss of retinal ganglion cell axons, along with impaired microvascular circulation and chronic inflammation, contribute to the pathogenesis of glaucoma, AMD, DR, and RVO. Geroprotectors, a class of longevity-promoting pharmacologic agents investigated for systemic benefits in cardiovascular and neurological aging, have therefore drawn growing ophthalmic interest for their potential relevance to ocular health and the management of age-associated eye diseases. These agents are now frequently encountered as concomitant medications in ophthalmic practice, yet their ocular effects remain incompletely characterized, variably reported, and in some cases controversial. Glucagon-like peptide-1 (GLP-1) receptor agonists, widely used for glycemic control and increasingly for weight management, have been associated with reduced risk of age-related glaucoma but also with unconfirmed reports of severe nonarteritic anterior ischemic optic neuropathy. Similar uncertainties surround other geroprotective, metabolic, and weight-modifying therapies, creating challenges for clinicians attempting to incorporate evolving pharmacologic evidence without compromising patient safety. This review synthesizes reported therapeutic and adverse ocular outcomes across geroprotective agents to support clinical awareness, identify knowledge gaps, and guide future investigation. The agents reviewed include GLP-1 receptor agonists, metformin, sodium-glucose cotransporter-2 inhibitors, statins, cannabinoids, calcium channel blockers, spermidine, taurine, nicotinamide adenine dinucleotide precursors, rapamycin, and mifepristone.<\/jats:p>","DOI":"10.1177\/10807683261456222","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:04:21Z","timestamp":1781240661000},"page":"530-544","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Geroprotective Agents, Including Glucagon-Like Peptide-1 Receptor Agonists, for Ocular Health"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0562-7893","authenticated-orcid":false,"given":"Alan","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aretha Y.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Khouri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.3884"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04252"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"e_1_3_3_6_1","first-page":"325","article-title":"Age-related eye disease and the pathophysiology of retinal aging","volume":"5","author":"Johnson LV","year":"2019","unstructured":"5.Johnson LV, et al. Age-related eye disease and the pathophysiology of retinal aging. Annu Rev Vis Sci 2019;5:325\u2013346.","journal-title":"Annu Rev Vis Sci"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-23-02033"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10827"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2025.01.010"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.1435"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae047"},{"issue":"9","key":"e_1_3_3_12_1","first-page":"1235","article-title":"GLP-1 receptor agonist use is associated with reduced risk for glaucoma","volume":"106","author":"Sterling J","year":"2022","unstructured":"11.Sterling J, , Hua P, , Dunaief JL, et al. GLP-1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol 2022;106(9):1235\u20131240.","journal-title":"Br J Ophthalmol"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.1440"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.10.029"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.6399"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.08.024"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9161039"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06132-5"},{"issue":"3","key":"e_1_3_3_19_1","first-page":"247","article-title":"Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: A retrospective cohort study and meta-analysis","volume":"142","author":"Kim HK","year":"2024","unstructured":"18.Kim HK, , Lee W, , Ryu IH, et al. Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: A retrospective cohort study and meta-analysis. JAMA Ophthalmol 2024;142(3):247\u2013255.","journal-title":"JAMA Ophthalmol"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2024.07.008"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06620-9"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.1455"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97889-1"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2025.03.002"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26321"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6555"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04031-z"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2419989"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6058"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01741-5"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.07.031"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.05.011"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/diabetology4030032"},{"issue":"6","key":"e_1_3_3_37_1","first-page":"567","article-title":"Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus","volume":"143","author":"Chuang CC","year":"2025","unstructured":"36.Chuang CC, , Wang K, , Chang CK, et al. Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus. JAMA Ophthalmol 2025;143(6):567\u2013574.","journal-title":"JAMA Ophthalmol"},{"key":"e_1_3_3_38_1","first-page":"1234567","article-title":"Association between sodium glucose cotransporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan","volume":"15","author":"Shao SC","year":"2024","unstructured":"37.Shao SC, , Su YC, , Lai ECC, et al. Association between sodium glucose cotransporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan. Front Pharmacol 2024;15:1234567.","journal-title":"Front Pharmacol"},{"key":"e_1_3_3_39_1","first-page":"617978","article-title":"New solutions for old challenges in glaucoma treatment: Is taurine an option to consider","volume":"8","author":"Iezhitsa I","year":"2021","unstructured":"38.Iezhitsa I, , Agarwal R. New solutions for old challenges in glaucoma treatment: Is taurine an option to consider? Front Med (Lausanne) 2021;8:617978.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"e_1_3_3_40_1","first-page":"1566","article-title":"Therapeutic effects of taurine and histidine supplementation in retinal diseases","volume":"14","author":"Lee D","year":"2024","unstructured":"39.Lee D, , Smith LEH. Therapeutic effects of taurine and histidine supplementation in retinal diseases. Life (Basel) 2024;14(12):1566.","journal-title":"Life (Basel)"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.09.010"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13818"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.032250"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000242"},{"issue":"12","key":"e_1_3_3_45_1","first-page":"1324","article-title":"UK Biobank Eye and Vision Consortium. Calcium channel blocker use and associated glaucoma and related traits among UK Biobank participants","volume":"130","author":"Kastner A","year":"2023","unstructured":"44.Kastner A, , Stuart KV, , Montesano G, et al. UK Biobank Eye and Vision Consortium. Calcium channel blocker use and associated glaucoma and related traits among UK Biobank participants. Ophthalmology 2023;130(12):1324\u20131334.","journal-title":"Ophthalmology"},{"issue":"2","key":"e_1_3_3_46_1","first-page":"465","article-title":"Amlodipine increases risk of primary open angle glaucoma","volume":"13","author":"Lehrer S","year":"2024","unstructured":"45.Lehrer S, , Rheinstein PH. Amlodipine increases risk of primary open angle glaucoma. Ophthalmol Ther 2024;13(2):465\u2013471.","journal-title":"Ophthalmol Ther"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.10.021"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-26422"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.2497"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092871"},{"issue":"4","key":"e_1_3_3_51_1","first-page":"313","article-title":"Protective effect of metformin against retinal vein occlusions in diabetes mellitus: A nationwide population-based study","volume":"55","author":"Lin TC","year":"2018","unstructured":"50.Lin TC, , Hwang DK, , Hsu CC, et al. Protective effect of metformin against retinal vein occlusions in diabetes mellitus: A nationwide population-based study. Acta Diabetol 2018;55(4):313\u2013319.","journal-title":"Acta Diabetol"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030660"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.05.039"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204248"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4342-z"},{"issue":"25","key":"e_1_3_3_57_1","first-page":"2408","article-title":"Cardioprotective and nephroprotective effects of SGLT2 inhibitors: Mechanisms and clinical implications","volume":"41","author":"Packer M","year":"2020","unstructured":"56.Packer M. Cardioprotective and nephroprotective effects of SGLT2 inhibitors: Mechanisms and clinical implications. Eur Heart J 2020;41(25):2408\u20132417.","journal-title":"Eur Heart J"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2080"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0353"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209805"},{"issue":"2","key":"e_1_3_3_62_1","article-title":"Exploring semaglutide beyond diabetes: The emergence of Ozempic in weight management and its societal implications","volume":"68","author":"Alagan L","year":"2024","unstructured":"61.Alagan L. Exploring semaglutide beyond diabetes: The emergence of Ozempic in weight management and its societal implications. Berkeley Sci J 2024;68(2). Available from: https:\/\/bsj.studentorg.berkeley.edu\/exploring-semaglutide-beyond-diabetes-the-emergence-of-ozempic-in-weight-management-and-its-societal-implications\/","journal-title":"Berkeley Sci J"},{"issue":"5","key":"e_1_3_3_63_1","first-page":"417","article-title":"Glucagon-like peptide 1 receptor agonists\u2014potential game changers in the treatment of glaucoma","volume":"140","author":"Mouhammad ZA","year":"2022","unstructured":"62.Mouhammad ZA, , Vohra R, , Horwitz A, et al. Glucagon-like peptide 1 receptor agonists\u2014potential game changers in the treatment of glaucoma? JAMA Ophthalmol 2022;140(5):417\u2013418.","journal-title":"JAMA Ophthalmol"},{"key":"e_1_3_3_64_1","first-page":"14","article-title":"The impact of GLP-1 receptor agonists on ocular disease","author":"Chapman R","year":"2025","unstructured":"63.Chapman R, , Allan K, , Talcott KE, et al. The impact of GLP-1 receptor agonists on ocular disease. Glaucoma Physician 2025:14\u201316.","journal-title":"Glaucoma Physician"},{"key":"e_1_3_3_65_1","first-page":"1089382","article-title":"Metformin protects trabecular meshwork against oxidative injury via activating integrin\/ROCK signals","volume":"13","author":"Zhang Y","year":"2023","unstructured":"64.Zhang Y, , Xu Y, , Liu Y. Metformin protects trabecular meshwork against oxidative injury via activating integrin\/ROCK signals. Front Pharmacol 2023;13:1089382.","journal-title":"Front Pharmacol"},{"key":"e_1_3_3_66_1","first-page":"109478","article-title":"Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: From molecular pathways to clinical impact","volume":"229","author":"Xie Z","year":"2025","unstructured":"65.Xie Z, , Yang Z, , Tian D, et al. Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: From molecular pathways to clinical impact. Exp Eye Res 2025;229:109478.","journal-title":"Exp Eye Res"},{"issue":"4","key":"e_1_3_3_67_1","first-page":"245","article-title":"Glucagon-like peptide-1 receptor agonists and the eye","volume":"36","author":"Coyne A","year":"2025","unstructured":"66.Coyne A. Glucagon-like peptide-1 receptor agonists and the eye. Curr Opin Ophthalmol 2025;36(4):245\u2013248.","journal-title":"Curr Opin Ophthalmol"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz069"},{"issue":"8","key":"e_1_3_3_69_1","first-page":"789","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"143","author":"Niazi S","year":"2025","unstructured":"68.Niazi S, , Gnesin F, , Thein AS, et al. Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes. JAMA Ophthalmol 2025;143(8):789\u2013797.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"e_1_3_3_70_1","first-page":"312","article-title":"Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes","volume":"143","author":"Muayad J","year":"2025","unstructured":"69.Muayad J, , Loya A, , Hussain ZS. Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes. JAMA Ophthalmol 2025;143(3):312\u2013319.","journal-title":"JAMA Ophthalmol"},{"key":"e_1_3_3_71_1","first-page":"45","article-title":"Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist","volume":"250","author":"Vasu P","year":"2025","unstructured":"70.Vasu P, , Dorairaj EA, , Weinreb RN, et al. Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist. Am J Ophthalmol 2025;250:45\u201352.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"e_1_3_3_72_1","first-page":"100234","article-title":"GLP-1 receptor agonists use and incidence of glaucoma: A systematic review and meta-analysis","volume":"5","author":"Amaral DC","year":"2025","unstructured":"71.Amaral DC, , Guedes J, , Cruz MRB. GLP-1 receptor agonists use and incidence of glaucoma: A systematic review and meta-analysis. Ophthalmol Sci 2025;5(3):100234.","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"e_1_3_3_73_1","first-page":"100245","article-title":"Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: A systematic review and meta-analysis","volume":"5","author":"Asif M","year":"2025","unstructured":"72.Asif M, , Asif A, , Rahman UA. Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: A systematic review and meta-analysis. Ophthalmol Sci 2025;5(4):100245.","journal-title":"Ophthalmol Sci"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.10.030"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16316"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.007"},{"key":"e_1_3_3_78_1","unstructured":"77.European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic Rybelsus and Wegovy. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy [Last accessed: September11 2025]."},{"key":"e_1_3_3_79_1","unstructured":"78.American Academy of Ophthalmology; North American Neuro-Ophthalmology Society. Should you stop taking GLP-1 drugs like Ozempic if you experience vision loss? Nation\u2019s ophthalmologists respond to European agency\u2019s new recommendation. 2025. Available from: https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/should-you-stop-taking-glp-1-drugs-like-ozempic [Last accessed: September11 2025]."},{"key":"e_1_3_3_80_1","unstructured":"79.American Optometric Association\u2013Evidence-Based Optometry Committee. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and ocular health: Guidance for optometric practice. Available from: https:\/\/www.aoa.org\/AOA\/Documents\/Practice%20Managementt\/Clinical%20Guidelines\/AOA%20GLP-1_EBO_clinical-report.pdf [Last accessed: September11 2025]."},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2251"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2017-000475"},{"key":"e_1_3_3_86_1","first-page":"1185786","article-title":"Metformin protects against retinal ischemia\/reperfusion injury through AMPK-mediated mitochondrial fusion","volume":"14","author":"Zhang Y","year":"2023","unstructured":"85.Zhang Y, , Xu Y, , Liu Y. Metformin protects against retinal ischemia\/reperfusion injury through AMPK-mediated mitochondrial fusion. Front Pharmacol 2023;14:1185786.","journal-title":"Front Pharmacol"},{"issue":"2","key":"e_1_3_3_87_1","first-page":"203","article-title":"Metformin use associated with protective effects for ocular complications in patients with type 2 diabetes: An observational study","volume":"14","author":"Male\u0161ki\u0107 S","year":"2017","unstructured":"86.Male\u0161ki\u0107 S, , Kusturica J, , Gu\u0161i\u0107 E, et al. Metformin use associated with protective effects for ocular complications in patients with type 2 diabetes: An observational study. Med Glas (Zenica) 2017;14(2):203\u2013208.","journal-title":"Med Glas (Zenica)"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179453"},{"issue":"12","key":"e_1_3_3_89_1","first-page":"5558","article-title":"Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p","volume":"9","author":"Zhang Y","year":"2017","unstructured":"88.Zhang Y, , Chen F, , Wang L. Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p. Am J Transl Res 2017;9(12):5558\u20135566.","journal-title":"Am J Transl Res"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/15353702211069986"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1649156"},{"key":"e_1_3_3_92_1","unstructured":"91.University of California San Francisco. Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration (METforMIN). ClinicalTrials.gov 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02684578 [Last accessed: September2 2025]."},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212384"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30153112"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48431"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-98997-8"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.4.58"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/174228"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1251798"},{"issue":"5","key":"e_1_3_3_100_1","first-page":"1234","article-title":"SGLT2 inhibitors can aid weight loss and reduce fat mass in people with type 2 diabetes: A systematic review and meta-analysis","volume":"25","author":"Campbell P","year":"2023","unstructured":"99.Campbell P, , Li Y, , Zhang X, et al. SGLT2 inhibitors can aid weight loss and reduce fat mass in people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2023;25(5):1234\u20131245.","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0195-z"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050711"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104970"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.5406"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004180"},{"issue":"1","key":"e_1_3_3_107_1","article-title":"Cannabinoid regulation of intraocular pressure: Human and animal studies, cellular and molecular targets","volume":"2","author":"Aloway A","year":"2017","unstructured":"106.Aloway A, , Kumar A, , Laun AS, et al. Cannabinoid regulation of intraocular pressure: Human and animal studies, cellular and molecular targets. Cannabis Cannabinoid Res 2017;2(1):3 13.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"6","key":"e_1_3_3_108_1","first-page":"591","article-title":"Cannabinoids and the eye","volume":"49","author":"Wang MTM","year":"2021","unstructured":"107.Wang MTM, , Danesh Meyer HV. Cannabinoids and the eye. Clin Exp Ophthalmol 2021;49(6):591\u2013601.","journal-title":"Clin Exp Ophthalmol"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123978"},{"issue":"6","key":"e_1_3_3_110_1","first-page":"1800","article-title":"Cannabinoids as new drug candidates for the treatment of glaucoma","volume":"27","author":"Jordan E","year":"2022","unstructured":"109.Jordan E, , Nguyen GN, , Piechot A, et al. Cannabinoids as new drug candidates for the treatment of glaucoma. Molecules 2022;27(6):1800.","journal-title":"Molecules"},{"issue":"2","key":"e_1_3_3_111_1","first-page":"87","article-title":"Facts vs fiction: The role of cannabinoids in the treatment of glaucoma","volume":"30","author":"Katz J","year":"2019","unstructured":"110.Katz J, , Costarides AP. Facts vs fiction: The role of cannabinoids in the treatment of glaucoma. Curr Opin Ophthalmol 2019;30(2):87\u201392.","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"e_1_3_3_112_1","first-page":"194","article-title":"The endocannabinoid system as a therapeutic target in glaucoma","volume":"30","author":"Cairns EA","year":"2016","unstructured":"111.Cairns EA, , Baldridge WH, , Kelly MEM. The endocannabinoid system as a therapeutic target in glaucoma. Eye (Lond) 2016;30(2):194\u2013201.","journal-title":"Eye (Lond)"},{"key":"e_1_3_3_113_1","first-page":"119","article-title":"\u03949 Tetrahydrocannabinol derivative loaded nanoformulation lowers intraocular pressure in normotensive rabbits","volume":"566","author":"Taskar PS","year":"2019","unstructured":"112.Taskar PS, , Patil A, , Lakhani P, et al. \u03949 Tetrahydrocannabinol derivative loaded nanoformulation lowers intraocular pressure in normotensive rabbits. Int J Pharm 2019;566:119\u2013127.","journal-title":"Int J Pharm"},{"key":"e_1_3_3_114_1","first-page":"213","article-title":"Pharmacological study of a cannabinoid containing eyedrop formulation in dogs and mice","volume":"111","author":"Stolf AM","year":"2016","unstructured":"113.Stolf AM, , Lugarini D, , De Oliveira A, et al. Pharmacological study of a cannabinoid containing eyedrop formulation in dogs and mice. Pharmacol Res 2016;111:213\u2013220.","journal-title":"Pharmacol Res"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2024.06.003"},{"issue":"1","key":"e_1_3_3_116_1","first-page":"131","article-title":"Efficacy and tolerability of topical 0.05% flunarizine in patients with open angle glaucoma or ocular hypertension: a pilot study","volume":"20","author":"Mansouri K","year":"2010","unstructured":"115.Mansouri K, , Silva SE, , Shaarawy T. Efficacy and tolerability of topical 0.05% flunarizine in patients with open angle glaucoma or ocular hypertension: a pilot study. Eur J Ophthalmol 2010;20(1):131\u2013137.","journal-title":"Eur J Ophthalmol"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.10.073"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.93"},{"key":"e_1_3_3_119_1","first-page":"681481","article-title":"Research progress and potential applications of spermidine in ocular diseases","volume":"12","author":"Han W","year":"2021","unstructured":"118.Han W, , Li H, , Chen B. Research progress and potential applications of spermidine in ocular diseases. Front Pharmacol 2021;12:681481.","journal-title":"Front Pharmacol"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-24938"},{"issue":"4","key":"e_1_3_3_121_1","first-page":"525","article-title":"Metabolomic profiling of aqueous humor in glaucoma points to taurine and spermine deficiency: Findings from the Eye-D study","volume":"8","author":"Buisset A","year":"2019","unstructured":"120.Buisset A, , Gohier P, , Leruez S, et al. Metabolomic profiling of aqueous humor in glaucoma points to taurine and spermine deficiency: Findings from the Eye-D study. J Clin Med 2019;8(4):525.","journal-title":"J Clin Med"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23258"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.3980\/j.issn.2222-3959.2014.01.31"},{"issue":"13","key":"e_1_3_3_124_1","first-page":"5165","article-title":"Taurine promotes retinal ganglion cell survival through GABA(B) receptor activation","volume":"57","author":"Hadj-Sa\u00efd W","year":"2016","unstructured":"123.Hadj-Sa\u00efd W, , Froger N, , Ivkovic I, et al. Taurine promotes retinal ganglion cell survival through GABA(B) receptor activation. Invest Ophthalmol Vis Sci 2016;57(13):5165\u20135174.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"e_1_3_3_125_1","first-page":"681","article-title":"Antiapoptotic effect of taurine against NMDA-induced retinal excitotoxicity in rats","volume":"35","author":"Lambuk L","year":"2019","unstructured":"124.Lambuk L, , Iezhitsa I, , Agarwal R, et al. Antiapoptotic effect of taurine against NMDA-induced retinal excitotoxicity in rats. Neurotox Res 2019;35(3):681\u2013692.","journal-title":"Neurotox Res"},{"issue":"12","key":"e_1_3_3_126_1","first-page":"2365","article-title":"Taurine protects transformed rat retinal ganglion cells from hypoxia-induced apoptosis by preventing mitochondrial dysfunction","volume":"34","author":"Chen K","year":"2009","unstructured":"125.Chen K, , Zhang Q, , Wang J, et al. Taurine protects transformed rat retinal ganglion cells from hypoxia-induced apoptosis by preventing mitochondrial dysfunction. Neurochem Res 2009;34(12):2365\u20132374.","journal-title":"Neurochem Res"},{"issue":"2","key":"e_1_3_3_127_1","first-page":"474","article-title":"Effect of magnesium acetyltaurate and taurine on endothelin-1-induced retinal nitrosative stress in rats","volume":"186","author":"Nor Arfuzir NN","year":"2018","unstructured":"126.Nor Arfuzir NN, , Agarwal R, , Iezhitsa I, et al. Effect of magnesium acetyltaurate and taurine on endothelin-1-induced retinal nitrosative stress in rats. Biol Trace Elem Res 2018;186(2):474\u2013484.","journal-title":"Biol Trace Elem Res"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01850-8"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal0092"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05243-3"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114137"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-024-01141-3"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177269"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113176"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052327"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2008.10.004"},{"key":"e_1_3_3_137_1","first-page":"100997","article-title":"Extracellular matrix regulation in the trabecular meshwork","volume":"87","author":"Keller KE","year":"2022","unstructured":"136.Keller KE, , Bhattacharya SK, , Borr\u00e1s T, et al. Extracellular matrix regulation in the trabecular meshwork. Prog Retin Eye Res 2022;87:100997.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"e_1_3_3_138_1","first-page":"80","article-title":"Increased myocilin expression in the trabecular meshwork of steroid treated glaucomatous eyes","volume":"42","author":"Wang WH","year":"2001","unstructured":"137.Wang WH, , McNatt LG, , Pang IH, et al. Increased myocilin expression in the trabecular meshwork of steroid treated glaucomatous eyes. Invest Ophthalmol Vis Sci 2001;42(1):80\u201385.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261456222","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261456222","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261456222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:18:03Z","timestamp":1789773483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261456222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":137,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1177\/10807683261456222"],"URL":"https:\/\/doi.org\/10.1177\/10807683261456222","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}